Amgen nabs new Blincyto approval for certain type of leukemia

The FDA on Friday gave its stamp of approval to Amgen’s Blincyto to treat both adults and children with the most common type of acute lymphoblastic leukemia, marking the third indication for the drug.

The approval is based on positive results from the NIH-funded Phase 3 E1910 clinical trial, which…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks